Literature DB >> 25667780

Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation.

Nergiz Dağoğlu1, Şule Karaman2, Alptekin Arifoğlu3, Seden Küçücük1, Ethem N Oral1.   

Abstract

Definitive radiotherapy plays a major role in the treatment of locally advanced non-small cell lung cancer (LA NSCLC). After the impact of RT dose for lung cancer was established, a number of trials were structured with the aim of better local control and overall survival by either dose escalation or shortening the total treatment time through conventional/altered fractionation, even in combination with chemotherapy (CT) and other targeted agents. In spite of the increased number of these studies, the optimal dose or fractionation still remains to be determined. Another aspect questioned is the incorporation of these higher doses and shorter treatment times with chemotherapy or targeted agents. This review summarises the results of significant trials on dose and altered fractionation in the treatment of LA-NSCLC with an emphasis on possible future perspectives.

Entities:  

Keywords:  Dose; fractionation; non-small cell lung cancer; radiotherapy

Year:  2014        PMID: 25667780      PMCID: PMC4318397          DOI: 10.5152/balkanmedj.2014.14496

Source DB:  PubMed          Journal:  Balkan Med J        ISSN: 2146-3123            Impact factor:   2.021


  33 in total

1.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.

Authors:  Jeffrey Bradley; Mary V Graham; Kathryn Winter; James A Purdy; Ritsuko Komaki; Wilson H Roa; Janice K Ryu; Walter Bosch; Bahman Emami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

2.  Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial.

Authors:  C Pöttgen; W Eberhardt; S Bildat; G Stüben; G Stamatis; L Hillejan; S Sohrab; H Teschler; S Seeber; H Sack; M Stuschke
Journal:  Ann Oncol       Date:  2002-03       Impact factor: 32.976

3.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Authors:  Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox
Journal:  J Natl Cancer Inst       Date:  2011-09-08       Impact factor: 13.506

4.  Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (chart) for patients with locally advanced inoperable non-small-cell lung cancer: the MRC INCH randomized trial.

Authors:  Matthew Hatton; Matthew Nankivell; Ethan Lyn; Stephen Falk; Cheryl Pugh; Neal Navani; Richard Stephens; Mahesh Parmar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

5.  A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.

Authors:  J D Cox; N Azarnia; R W Byhardt; K H Shin; B Emami; T F Pajak
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

6.  Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.

Authors:  Joseph K Salama; Thomas E Stinchcombe; Lin Gu; Xiaofei Wang; Karen Morano; Jeffrey A Bogart; Jeffrey C Crawford; Mark A Socinski; A William Blackstock; Everett E Vokes
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-07       Impact factor: 7.038

7.  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.

Authors:  W T Sause; C Scott; S Taylor; D Johnson; R Livingston; R Komaki; B Emami; W J Curran; R W Byhardt; A T Turrisi
Journal:  J Natl Cancer Inst       Date:  1995-02-01       Impact factor: 13.506

8.  Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.

Authors:  Mark A Socinski; A William Blackstock; Jeffrey A Bogart; Xiaofei Wang; Michael Munley; Julian Rosenman; Lin Gu; Gregory A Masters; Peter Ungaro; Arthur Sleeper; Mark Green; Antonius A Miller; Everett E Vokes
Journal:  J Clin Oncol       Date:  2008-05-20       Impact factor: 44.544

9.  Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.

Authors:  B Jeremic; Y Shibamoto; L Acimovic; L Djuric
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

10.  Once-a-week vs conventional daily radiation treatment for lung cancer: final report.

Authors:  R G Slawson; O M Salazar; H Poussin-Rosillo; P P Amin; R Strohl; W Sewchand
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-07       Impact factor: 7.038

View more
  3 in total

1.  Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy.

Authors:  Juyi Wen; Hongliang Liu; Lili Wang; Xiaomeng Wang; Ning Gu; Zhensheng Liu; Ting Xu; Daniel R Gomez; Ritsuko Komaki; Zhongxing Liao; Qingyi Wei
Journal:  J Thorac Oncol       Date:  2018-02-15       Impact factor: 15.609

2.  Caspase-3 knockout attenuates radiation-induced tumor repopulation via impairing the ATM/p53/Cox-2/PGE2 pathway in non-small cell lung cancer.

Authors:  Minghui Zhao; Yiwei Wang; Yucui Zhao; Sijia He; Ruyi Zhao; Yanwei Song; Jin Cheng; Yanping Gong; Jianzhu Xie; Yulan Wang; Binjie Hu; Ling Tian; Qian Huang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

3.  Dosimetric evaluation of a simple planning method for improving intensity-modulated radiotherapy for stage III lung cancer.

Authors:  Jia-Yang Lu; Zhu Lin; Jing Zheng; Pei-Xian Lin; Michael Lok-Man Cheung; Bao-Tian Huang
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.